Nobuo Tsutsumi - Hisamitsu Pharmaceutical Director
| HTSUFDelisted Stock | USD 30.31 0.00 0.00% |
Director
Mr. Nobuo Tsutsumi was serving as Executive Officer, Director of Legal Affairs and Director in Hisamitsu Pharmaceutical Co., Inc. since May 22, 2014. He joined the Company in April 1988. since 2014.
| Age | 59 |
| Tenure | 10 years |
| Phone | 81 3 5293 1720 |
| Web | https://www.hisamitsu.co.jp |
Hisamitsu Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0212 % which means that it generated a profit of $0.0212 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0504 %, meaning that it generated $0.0504 on every $100 dollars invested by stockholders. Hisamitsu Pharmaceutical's management efficiency ratios could be used to measure how well Hisamitsu Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Hisamitsu Pharmaceutical Co has accumulated 219 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Hisamitsu Pharmaceutical has a current ratio of 4.37, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hisamitsu Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Hisamitsu Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hisamitsu Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hisamitsu to invest in growth at high rates of return. When we think about Hisamitsu Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Shiro Kuniya | Takeda Pharmaceutical Co | 63 | |
| Sarah Kavanagh | Bausch Health Companies | 63 | |
| Andrew Eschenbach | Bausch Health Companies | 78 | |
| Argeris Karabelas | Bausch Health Companies | 66 | |
| John Paulson | Bausch Health Companies | 64 | |
| Toshiyuki Shiga | Takeda Pharmaceutical Co | 67 | |
| Richard Schutter | Bausch Health Companies | 79 | |
| Yoshiaki Fujimori | Takeda Pharmaceutical Co | 69 | |
| James Jenness | Prestige Brand Holdings | 73 | |
| Michel Orsinger | Takeda Pharmaceutical Co | 62 | |
| JeanLuc Butel | Takeda Pharmaceutical Co | 64 | |
| Thomas Ross | Bausch Health Companies | 69 | |
| John Byom | Prestige Brand Holdings | 66 | |
| Natale Ricciardi | Prestige Brand Holdings | 71 | |
| Sheila Hopkins | Prestige Brand Holdings | 64 | |
| Gary Costley | Prestige Brand Holdings | 55 | |
| Koji Hatsukawa | Takeda Pharmaceutical Co | 68 | |
| Philip CFA | Prestige Brand Holdings | N/A | |
| Amy Wechsler | Bausch Health Companies | 50 | |
| Dawn Zier | Prestige Brand Holdings | 55 | |
| Celeste Clark | Prestige Brand Holdings | 67 | |
Management Performance
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 |
Hisamitsu Pharmaceutical Leadership Team
Elected by the shareholders, the Hisamitsu Pharmaceutical's board of directors comprises two types of representatives: Hisamitsu Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hisamitsu. The board's role is to monitor Hisamitsu Pharmaceutical's management team and ensure that shareholders' interests are well served. Hisamitsu Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hisamitsu Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kyu Saito, Executive Officer, Director of International Business, Chairman of Subsidiaries, Director | ||
| Shinichiro Takao, General Manager of IR Department, Treasurer and Director | ||
| Mitsutoshi Tsuruta, Ex Division | ||
| Masaya Okuno, OTC Division | ||
| Kazuhide Nakatomi, President, COO and Executive VP | ||
| Koji Takiyama, Executive Officer, Manager of President's Office | ||
| Kosuke Sugiyama, Senior Managing Director, Executive Officer, Director of Human Resource | ||
| Shinichi Murayama, Executive Officer, Manager of President's Office in Kyushu Headquarters, Director | ||
| Nobuo Tsutsumi, Executive Officer, Director of Legal Affairs, Director | ||
| Mitsumasa Kabashima, Pres Ltd |
Hisamitsu Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hisamitsu Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.15 B | |||
| Shares Outstanding | 79.53 M | |||
| Shares Owned By Insiders | 26.45 % | |||
| Shares Owned By Institutions | 35.26 % | |||
| Price To Earning | 22.53 X | |||
| Price To Book | 0.97 X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Hisamitsu Pink Sheet
If you are still planning to invest in Hisamitsu Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hisamitsu Pharmaceutical's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |